Glucagon Receptor Activity May increase energy expenditure and fat oxidation pathways, which is one reason Retatrutide is being studied as a next-generation obesity medication
Originally approved for diabetes management, glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide have rapidly crossed over into mainstream aesthetic practice by delivering dramatic weight loss in remarkably short time frames
The study compared patients who were taking GLP-1 medications with an equal number of matched patients who were not using the drugs
Although strict glycemic control has beneficial effects on microvascular complications (retinopathy, nephropathy or neuropathy), it does not seem to reduce the risk of cardiovascular disease, and it is associated with an increased risk of hypoglycemia in patients with DM2.3,6 Until recently, the antihyperglycemic drugs available have improved glycemic control, but without much benefits on cardiovascular and/or renal risk
[10] [11] Because it stimulates GH release, it may exacerbate conditions sensitive to GH excess, such as diabetic retinopathy or carpal tunnel syndrome
However, while around 12% Americans use them and they are intended to be taken long-term, the majority stop taking them within a year
